Loading...

Innophos Holdings

Nasdaq:IPHS
Snowflake Description

Good value average dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IPHS
Nasdaq
$570M
Market Cap
  1. Home
  2. US
  3. Materials
Company description

Innophos Holdings, Inc., together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
IPHS Share Price and Events
7 Day Returns
-3.8%
NasdaqGS:IPHS
-0.6%
US Chemicals
-0.7%
US Market
1 Year Returns
-39.1%
NasdaqGS:IPHS
-15.4%
US Chemicals
3%
US Market
IPHS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Innophos Holdings (IPHS) -3.8% -8.9% -8.8% -39.1% -20.8% -45.4%
US Chemicals -0.6% -7.8% -8.9% -15.4% 16.9% 6.7%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • IPHS underperformed the Chemicals industry which returned -15.4% over the past year.
  • IPHS underperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
IPHS
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Innophos Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Innophos Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Innophos Holdings.

NasdaqGS:IPHS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:IPHS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Chemicals Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.87 (1 + (1- 21%) (67.27%))
1.223
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.22
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.223 * 5.96%)
10.02%

Discounted Cash Flow Calculation for NasdaqGS:IPHS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Innophos Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:IPHS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.02%)
2019 8.43 Est @ -50.81% 7.66
2020 5.50 Est @ -34.75% 4.54
2021 4.21 Est @ -23.5% 3.16
2022 3.55 Est @ -15.63% 2.42
2023 3.19 Est @ -10.12% 1.98
2024 2.99 Est @ -6.27% 1.69
2025 2.88 Est @ -3.57% 1.48
2026 2.84 Est @ -1.68% 1.32
2027 2.83 Est @ -0.36% 1.20
2028 2.84 Est @ 0.57% 1.09
Present value of next 10 years cash flows $26.55
NasdaqGS:IPHS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $2.84 × (1 + 2.73%) ÷ (10.02% – 2.73%)
$40.06
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $40.06 ÷ (1 + 10.02%)10
$15.42
NasdaqGS:IPHS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $26.55 + $15.42
$41.97
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $41.97 / 19.52
$2.15
NasdaqGS:IPHS Discount to Share Price
Calculation Result
Value per share (USD) From above. $2.15
Current discount Discount to share price of $29.20
= -1 x ($29.20 - $2.15) / $2.15
-1258.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Innophos Holdings is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Innophos Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Innophos Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:IPHS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $1.73
NasdaqGS:IPHS Share Price ** NasdaqGS (2019-05-17) in USD $29.2
United States of America Chemicals Industry PE Ratio Median Figure of 67 Publicly-Listed Chemicals Companies 17.88x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Innophos Holdings.

NasdaqGS:IPHS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:IPHS Share Price ÷ EPS (both in USD)

= 29.2 ÷ 1.73

16.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innophos Holdings is good value based on earnings compared to the US Chemicals industry average.
  • Innophos Holdings is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Innophos Holdings's expected growth come at a high price?
Raw Data
NasdaqGS:IPHS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
21.3%per year
United States of America Chemicals Industry PEG Ratio Median Figure of 49 Publicly-Listed Chemicals Companies 1.33x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

NasdaqGS:IPHS PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 16.92x ÷ 21.3%

0.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innophos Holdings is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Innophos Holdings's assets?
Raw Data
NasdaqGS:IPHS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $17.81
NasdaqGS:IPHS Share Price * NasdaqGS (2019-05-17) in USD $29.2
United States of America Chemicals Industry PB Ratio Median Figure of 93 Publicly-Listed Chemicals Companies 2.09x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqGS:IPHS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:IPHS Share Price ÷ Book Value per Share (both in USD)

= 29.2 ÷ 17.81

1.64x

* Primary Listing of Innophos Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innophos Holdings is good value based on assets compared to the US Chemicals industry average.
X
Value checks
We assess Innophos Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check)
  5. Innophos Holdings has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Innophos Holdings expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Innophos Holdings expected to grow at an attractive rate?
  • Innophos Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Innophos Holdings's earnings growth is expected to exceed the United States of America market average.
  • Innophos Holdings's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:IPHS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:IPHS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 21.3%
NasdaqGS:IPHS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 1.9%
United States of America Chemicals Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
United States of America Chemicals Industry Revenue Growth Rate Market Cap Weighted Average 4.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:IPHS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:IPHS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 808 133 51 3
2019-12-31 787 89 44 3
NasdaqGS:IPHS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 788 63 34
2018-12-31 802 74 36
2018-09-30 802 64 20
2018-06-30 789 72 17
2018-03-31 762 86 22
2017-12-31 722 74 22
2017-09-30 697 104 43
2017-06-30 699 116 45
2017-03-31 702 132 46
2016-12-31 725 139 48
2016-09-30 728 105 34
2016-06-30 742 86 26

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Innophos Holdings's earnings are expected to grow significantly at over 20% yearly.
  • Innophos Holdings's revenue is expected to grow by 1.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:IPHS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Innophos Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:IPHS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 2.57 2.65 2.50 3.00
2019-12-31 2.21 2.23 2.18 3.00
NasdaqGS:IPHS Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 1.73
2018-12-31 1.84
2018-09-30 1.02
2018-06-30 0.89
2018-03-31 1.15
2017-12-31 1.15
2017-09-30 2.21
2017-06-30 2.32
2017-03-31 2.37
2016-12-31 2.47
2016-09-30 1.75
2016-06-30 1.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Innophos Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Innophos Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Innophos Holdings has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Innophos Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Innophos Holdings's growth in the last year to its industry (Chemicals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Innophos Holdings's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Innophos Holdings's 1-year earnings growth exceeds its 5-year average (50.6% vs -17.8%)
  • Innophos Holdings's earnings growth has exceeded the US Chemicals industry average in the past year (50.6% vs 14.2%).
Earnings and Revenue History
Innophos Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Innophos Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:IPHS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 787.82 33.72 77.46 5.01
2018-12-31 801.84 35.94 80.53 5.08
2018-09-30 802.20 19.97 85.97 5.01
2018-06-30 789.11 17.45 84.95 4.83
2018-03-31 761.52 22.39 82.33 4.31
2017-12-31 722.02 22.37 79.13 3.73
2017-09-30 696.71 42.87 71.43 3.54
2017-06-30 698.91 44.90 70.67 3.37
2017-03-31 701.66 45.76 66.52 3.57
2016-12-31 725.35 47.68 66.26 3.74
2016-09-30 728.19 33.71 62.42 3.99
2016-06-30 741.76 25.58 68.04 4.28
2016-03-31 777.17 27.14 70.97 4.32
2015-12-31 789.15 26.27 70.20 4.50
2015-09-30 813.00 42.22 77.97 4.82
2015-06-30 822.21 55.08 74.02 4.79
2015-03-31 824.45 62.10 75.04 4.81
2014-12-31 839.19 64.32 76.02 4.65
2014-09-30 841.22 67.61 75.13 4.79
2014-06-30 852.40 60.25 72.86 4.45
2014-03-31 846.03 51.21 71.12 4.19
2013-12-31 844.13 49.44 70.50 3.93
2013-09-30 856.39 48.25 67.38 3.19
2013-06-30 847.58 54.02 67.65 3.14
2013-03-31 848.59 58.95 64.94 3.17
2012-12-31 862.40 74.15 64.32 3.11
2012-09-30 862.78 81.71 68.11 3.04
2012-06-30 853.69 83.87 66.04 3.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Innophos Holdings has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Innophos Holdings used its assets less efficiently than the US Chemicals industry average last year based on Return on Assets.
  • Innophos Holdings's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Innophos Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Innophos Holdings has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Innophos Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Innophos Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Innophos Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Innophos Holdings's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Innophos Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Innophos Holdings Company Filings, last reported 1 month ago.

NasdaqGS:IPHS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 346.55 383.44 21.17
2018-12-31 335.52 300.00 20.20
2018-09-30 340.67 345.01 23.08
2018-06-30 334.97 330.01 12.27
2018-03-31 336.21 345.01 40.72
2017-12-31 333.56 310.01 28.78
2017-09-30 353.77 295.01 32.73
2017-06-30 351.15 180.00 33.50
2017-03-31 348.32 189.00 29.80
2016-12-31 347.23 185.00 53.49
2016-09-30 345.37 199.17 32.80
2016-06-30 339.82 229.00 39.21
2016-03-31 336.02 229.84 15.43
2015-12-31 333.26 213.00 17.91
2015-09-30 342.37 286.00 86.05
2015-06-30 384.72 244.00 79.99
2015-03-31 430.97 205.01 57.25
2014-12-31 463.01 136.01 36.21
2014-09-30 477.90 128.01 45.16
2014-06-30 476.18 139.01 38.47
2014-03-31 470.06 155.01 43.34
2013-12-31 463.42 163.01 32.76
2013-09-30 459.37 162.01 35.80
2013-06-30 455.17 168.02 32.39
2013-03-31 448.69 154.00 26.19
2012-12-31 444.32 176.00 26.82
2012-09-30 439.05 117.00 36.57
2012-06-30 427.75 133.00 70.17
  • Innophos Holdings's level of debt (110.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (32.9% vs 110.6% today).
  • Debt is not well covered by operating cash flow (16.3%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.5x coverage).
X
Financial health checks
We assess Innophos Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Innophos Holdings has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Innophos Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
6.58%
Current annual income from Innophos Holdings dividends.
If you bought $2,000 of Innophos Holdings shares you are expected to receive $132 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Innophos Holdings's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
  • Innophos Holdings's dividend is above the markets top 25% of dividend payers in United States of America (3.69%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:IPHS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Chemicals Industry Average Dividend Yield Market Cap Weighted Average of 54 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:IPHS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
NasdaqGS:IPHS Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-04-30 1.920 6.098
2019-02-20 1.920 6.044
2018-11-01 1.920 7.020
2018-07-30 1.920 4.701
2018-05-01 1.920 4.007
2018-02-21 1.920 4.611
2017-10-31 1.920 4.243
2017-08-01 1.920 4.074
2017-05-02 1.920 4.408
2017-02-22 1.920 3.801
2016-10-28 1.920 3.750
2016-08-02 1.920 4.781
2016-05-02 1.920 4.768
2016-02-23 1.920 6.179
2015-11-04 1.920 6.742
2015-07-30 1.920 4.268
2015-04-30 1.920 3.691
2015-01-29 1.920 3.329
2014-10-30 1.920 3.358
2014-07-30 1.920 3.321
2014-05-09 1.600 2.882
2014-01-31 1.600 3.020
2013-10-28 1.600 3.322
2013-07-31 1.400 2.701
2013-05-03 1.400 2.786
2013-02-01 1.400 2.691
2012-10-31 1.400 2.894
2012-06-20 1.080 2.124
2012-02-21 1.080 2.195
2011-12-08 1.000 2.032
2011-09-29 1.000 2.267
2011-05-26 1.000 2.293
2011-03-21 1.000 2.235
2010-12-09 0.680 1.812
2010-10-11 0.680 1.957
2010-06-16 0.680 2.362
2010-03-12 0.680 2.433
2009-12-14 0.680 3.130
2009-09-28 0.680 3.108
2009-06-12 0.680 3.801

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Innophos Holdings's earnings are paid to the shareholders as a dividend.
  • Dividends paid are not well covered by earnings (0.9x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Innophos Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Innophos Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Innophos Holdings has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Innophos Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kim Mink
COMPENSATION $3,353,966
AGE 58
TENURE AS CEO 3.4 years
CEO Bio

Dr. Kim Ann Mink, Ph.D., has been the Chief Executive Officer and President at Innophos Holdings Inc. since December 14, 2015. Dr. Mink serves as the President of CanStates Holdings, Inc. She has been a Director of Eastman Chemical Company since July 1, 2018. She served as the Chief Executive Officer of ANGUS Chemical Company since October 2009 and served as its President from October 2009 to October 2010. She served as General Manager for the Worldwide Ion Exchange Resins Business at Rohm and Haas Company. She served as the Business President of Elastomers, Electrical and Telecommunications at The Dow Chemical Company from September 2012 to February 22, 2016. She served as Global General Manager of Ion Exchange Resins Process Chemicals & Biocides. She joined Rohm and Haas in 1988 as a Group Leader in the Analytical Research Department. In 1991, Dr. Mink became the Corporate Regulatory Affairs Manager in the Product Integrity Department with responsibility of managing programs to obtain and maintain FDA approvals for the use of Rohm and Haas products in FDA areas. Since 1995, she has several commercial roles of increasing responsibility, regionally and globally, including, NAR Account Manager, Petroleum Chemicals, Americas Marketing Manager and NAR Commercial Manager of Consumer and Industrial Specialties, Global General Manager for the Water Business in Process Chemicals and Americas General Manager for Process Chemicals. She served as Vice President at Rohm and Haas Company since 2007. Prior to joining Dow Chemical in 2009, she had previously served for more than 20 years at the Rohm and Haas Company (which was acquired by Dow Chemical) where she held roles of increasing responsibility, including corporate vice president and general manager for the Ion Exchange Resins business. Dr. Mink joined Dow in April 2009 as Global General Manager. She has been Chairman of the Board at Innophos Holdings, Inc. since February 21, 2017. She has been a Director of Innophos Holdings Inc. since January 2016 and Independent Director of PolyOne Corporation since March 2017. She has been a Member of National Board of Trustees at ALS Association since November 2012. She served as a Member of Advisory Board at Catalyst Inc. since September 2012 until December 2015. In 2014, Dr. Mink was named to STEMconnector's 100 Diverse Corporate Leaders in STEM. Dr. Mink received her BA in Chemistry from Hamilton College and a PhD in Analytical Chemistry from Duke University. She is a graduate of the Wharton School of Business Management Program.

CEO Compensation
  • Kim's compensation has been consistent with company performance over the past year.
  • Kim's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Innophos Holdings management team in years:

2
Average Tenure
58
Average Age
  • The tenure for the Innophos Holdings management team is about average.
Management Team

Kim Mink

TITLE
Chairman of the Board
COMPENSATION
$3M
AGE
58
TENURE
3.4 yrs

Sherry Duff

TITLE
Senior VP and Chief Marketing & Technology Officer
COMPENSATION
$725K
AGE
50
TENURE
2.8 yrs

Josh Horenstein

TITLE
Senior VP
COMPENSATION
$814K
AGE
41
TENURE
3.2 yrs

Mark Santangelo

TITLE
Senior Vice President of Manufacturing
COMPENSATION
$777K
AGE
60
TENURE
2 yrs

Mark Feuerbach

TITLE
Chief Financial Officer
COMPENSATION
$752K
AGE
59
TENURE
0.2 yrs

William Dunworth

TITLE
VP, Corporate Controller & Chief Accounting Officer
AGE
42
TENURE
0.6 yrs

Amy Hartzell

TITLE
Senior Vice President of Supply Chain & Purchasing
COMPENSATION
$538K
AGE
42
TENURE
2 yrs

James Testa

TITLE
Assistant Secretary
AGE
70

Yasef Murat

TITLE
Senior Manufacturing Fellow
COMPENSATION
$570K
AGE
63
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the Innophos Holdings board of directors in years:

6.8
Average Tenure
62
Average Age
  • The tenure for the Innophos Holdings board of directors is about average.
Board of Directors

Kim Mink

TITLE
Chairman of the Board
COMPENSATION
$3M
AGE
58
TENURE
2.3 yrs

Gary Cappeline

TITLE
Director
COMPENSATION
$235K
AGE
68
TENURE
12.3 yrs

John Steitz

TITLE
Independent Director
COMPENSATION
$210K
AGE
59
TENURE
10.3 yrs

Bob Zatta

TITLE
Independent Director
COMPENSATION
$208K
AGE
68
TENURE
3.3 yrs

Peter Thomas

TITLE
Lead Independent Director
COMPENSATION
$219K
AGE
62
TENURE
1.1 yrs

Linda Myrick

TITLE
Independent Director
COMPENSATION
$189K
AGE
62
TENURE
12.6 yrs

Karen Osar

TITLE
Independent Director
COMPENSATION
$198K
AGE
69
TENURE
11.6 yrs

Jane Hilk

TITLE
Director
COMPENSATION
$11K
AGE
58
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Innophos Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Innophos Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Now An Opportune Moment To Examine Innophos Holdings, Inc. (NASDAQ:IPHS)?

Less-covered, small caps sees more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing? … So, could the stock still be trading at a low price relative to its actual value. … Today I will analyse the most recent data on Innophos Holdings’s outlook and valuation to see if the opportunity still exists

Simply Wall St -

Are Dividend Investors Getting More Than They Bargained For With Innophos Holdings, Inc.'s (NASDAQ:IPHS) Dividend?

(NASDAQ:IPHS) be an attractive dividend share to own for the long haul? … Yet sometimes, investors buy a stock for its dividend and lose money because the share price falls by more than they earned in dividend payments. … With Innophos Holdings yielding 6.1% and having paid a dividend for over 10 years, many investors likely find the company quite interesting.

Simply Wall St -

Imagine Owning Innophos Holdings (NASDAQ:IPHS) And Wondering If The 38% Share Price Slide Is Justified

After all, the share price is down 38% in that time, significantly under-performing the market. … By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … Looking back five years, both Innophos Holdings's share price and EPS declined; the latter at a rate of 4.0% per year.

Simply Wall St -

How Financially Strong Is Innophos Holdings, Inc. (NASDAQ:IPHS)?

(NASDAQ:IPHS) with its market cap of US$609m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Understanding the company's financial health becomes. … The following basic checks can help you get a picture of the company's balance sheet strength.

Simply Wall St -

Does Innophos Holdings, Inc. (NASDAQ:IPHS) Have A Good P/E Ratio?

We'll show how you can use Innophos Holdings, Inc.'s (NASDAQ:IPHS) P/E ratio to inform your assessment of the investment opportunity. … Based on the last twelve months, Innophos Holdings's P/E ratio is 16.61. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Based On Its ROE, Is Innophos Holdings, Inc. (NASDAQ:IPHS) A High Quality Stock?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Our data shows Innophos Holdings has a return on equity of 5.9% for the last year. … That means that for every $1 worth of shareholders' equity, it generated $0.059 in profit.

Simply Wall St -

Should You Be Pleased About The CEO Pay At Innophos Holdings, Inc.'s (NASDAQ:IPHS)

First, this article will compare CEO compensation with compensation at similar sized companies. … View our latest analysis for Innophos Holdings … How Does Kim Mink's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Does The Innophos Holdings, Inc. (NASDAQ:IPHS) Share Price Fall With The Market?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What You Must Know About Innophos Holdings, Inc.'s (NASDAQ:IPHS) Financial Strength

(NASDAQ:IPHS) with its market cap of US$488m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Evaluating financial health as part of your investment thesis is. … Here are a few basic checks that are good enough to have a broad overview of the company’s financial strength.

Simply Wall St -

Is It Time To Consider Buying Innophos Holdings Inc (NASDAQ:IPHS)?

Innophos Holdings Inc (NASDAQ:IPHS), which is in the chemicals business, and is based in United States,. … A question to answer is whether Innophos Holdings's current trading price of $26.76 reflective of the actual value of the? … Let’s take a look at Innophos Holdings’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change

Simply Wall St -

Company Info

Description

Innophos Holdings, Inc., together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company’s specialty ingredients include specialty phosphate products, specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste. It also provides food and technical grade purified phosphoric acid (PPA) used in the production of phosphate salts, as well as in food and beverages, and water treatment applications; technical grade sodium tripolyphosphate (STPP), a specialty phosphate, which is used as an ingredient in cleaning products, such as industrial and institutional cleaners, automatic dishwashing detergents, and consumer laundry detergents, as well as in water treatment, clay processing, and copper ore processing activities; and detergent grade PPA that is primarily used in the production of STPP. In addition, the company offers granular triple super-phosphate (GTSP), a fertilizer product line used for enhancing crop yields in various agricultural sectors; and merchant green phosphoric acid. It serves primarily consumer goods manufacturers, distributors, and specialty chemical manufacturers in the United States, Canada, Mexico, and internationally. Innophos Holdings, Inc. was founded in 2004 and is headquartered in Cranbury, New Jersey.

Details
Name: Innophos Holdings, Inc.
IPHS
Exchange: NasdaqGS
Founded: 2004
$570,023,040
19,521,337
Website: http://www.innophos.com
Address: Innophos Holdings, Inc.
259 Prospect Plains Road,
Cranbury,
New Jersey, 08512,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS IPHS Common Stock Nasdaq Global Select US USD 02. Nov 2006
DB HQ9 Common Stock Deutsche Boerse AG DE EUR 02. Nov 2006
BMV IPHS * Common Stock Bolsa Mexicana de Valores MX MXN 02. Nov 2006
Number of employees
Current staff
Staff numbers
1,485
Innophos Holdings employees.
Industry
Specialty Chemicals
Materials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 02:05
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/06
Last earnings filing: 2019/05/01
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.